Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

A gap between biological and chronological age could signal MS progression before symptoms appear. Researchers found that people with MS showed accelerated proteomic aging — even years before diagnosis — and that larger age gaps correlated with greater disability. This opens the door to earlier detection and more targeted treatment strategies.
Researchers at Johns Hopkins University have found that a gap between proteomic (biological) age and chronological age may predict multiple sclerosis (MS) progression — and even flag risk before symptoms begin. Presented at the American Neurological Association's 151st annual meeting, the findings suggest that "aging clocks" based on blood proteins could become a powerful tool for early MS detection in high-risk populations.
The study analyzed blood samples from two cohorts: a Department of Defense repository with presymptomatic and post-onset MS samples, and a Hopkins cohort of patients with established MS. Using SomaScan and Olink aging clocks, researchers measured systemic and organ-specific proteomic ages and compared them to what would be expected based on chronological age.
By the Numbers:
Why it matters: These findings could reshape how clinicians monitor and treat MS — enabling earlier intervention before irreversible damage occurs and offering a measurable biomarker for use in clinical trials.